cetrimide
Cetrimide, or alkyltrimethylammonium bromide, is an antiseptic which is a mixture of three quaternary ammonium compounds: tetradonium bromide, cetrimonium bromide (CTAB), and laurtrimonium bromide. It was first discovered and developed by ICI and introduced under the brand name Cetavlon. It is used as a 1-3 % solution for cleaning roadside accident wounds. ICI also introduced Savlon, which was a combination of cetrimide and chlorhexidine. ICI sold the Savlon brand OTC to Johnson & Johnson in May 1992. Cetrimide is used in various applications such as antiseptic agents, diagnostic test and analysis, topical formulations, and dental treatment. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jan 15, 2019 (NCT03865147)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetSurfactant
surfactant
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCetrimide ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03865147 | Phase 2 | Jan 15, 2019 | Medical Ethics UK Ltd, ProTherax Ltd, Welsh Wound Innovation Centre Ltd |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medical Ethics UK Ltd | For profit | 1 | 1 | 1 | 2019 |
| ProTherax Ltd | For profit | 1 | 0 | 1 | 2019 |
| Welsh Wound Innovation Centre Ltd | Academic/Hospital | 1 | 0 | 1 | 2019 |